Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

PBRM1 mutations not quite up to snuff as ccRCC biomarkers

Publish date:: September 13, 2019

Key clinical point: Patients with clear cell renal cell carcinoma and PBRM1 mutations had better responses and survival with nivolumab.

Major finding: Nivolumab-treated patients with mutations had more than 100% better response rates, progression-free survival, and overall survival versus patients without mutations.

Study details: An independent cohort of 382 patients with metastatic clear cell renal cell carcinoma in a phase 3 trial.

Disclosures: The study was supported by Department of Defense Congressionally Directed Medical Research Programs and Bristol-Myers Squibb. Dr. Choueri disclosed personal fees from Bristol-Myers Squibb and fees and grants from other companies. One coauthor Alice M Walsh PhD is a Bristol-Myers Squibb employee and shareholder.

Citation:

Choueiri TK et al. JAMA Oncol. 2019 Sep 5. doi: 10.1001/jamaoncol.2019.3158.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Genitourinary Cancer

Study shows no link between race and mortality in clear cell RCC,

Four factors may predict better survival with cabozantinib in mRCC,

Focal radiation boost nets better outcomes in prostate cancer,

Fear of recurrence highly prevalent in RCC survivors,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,